MARX Biotech (7731) 주식 개요는 남성 건강 및 코스메슈티컬 제품의 온라인 소매업에 종사하고 있습니다. 자세히 보기7731 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적2/6재무 건전성2/6배당1/6강점올해부터 흑자전환위험 분석부채는 operating cash flow로 충분히 감당되지 않습니다.높은 수준의 비현금 수입지난 3개월 동안 주가 변동성이 TW 시장과 비교해 높았습니다.의미 있는 시가총액이 없습니다(NT$3B)모든 위험 점검 보기7731 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$5.6050.9% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-97m636m2016201920222025202620282031Revenue NT$635.9mEarnings NT$42.9mAdvancedSet Fair ValueView all narrativesMARX Biotech Co., Ltd. 경쟁사MedFirst Healthcare ServicesSymbol: TPEX:4175Market cap: NT$2.3bNorbel BabySymbol: TPEX:6844Market cap: NT$2.4bGreat Tree PharmacySymbol: TPEX:6469Market cap: NT$11.4bTait Marketing & DistributionSymbol: TPEX:5902Market cap: NT$3.4b가격 이력 및 성과MARX Biotech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NT$5.6052주 최고가NT$10.6052주 최저가NT$3.90베타0.601개월 변동-8.50%3개월 변동7.07%1년 변동-3.11%3년 변동n/a5년 변동n/aIPO 이후 변동-36.36%최근 뉴스 및 업데이트공시 • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).더 많은 업데이트 보기Recent updates공시 • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).공시 • Mar 28MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025, at 09:30 Taipei Standard Time. Location: 13 floor no,659, pan nan rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).New Risk • Jan 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.28b market cap, or US$99.6m).공시 • Mar 16MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024.주주 수익률7731TW Consumer RetailingTW 시장7D-0.4%-2.5%-2.0%1Y-3.1%-14.2%99.7%전체 주주 수익률 보기수익률 대 산업: 7731은 지난 1년 동안 -14.2%의 수익을 기록한 TW Consumer Retailing 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 7731은 지난 1년 동안 99.7%를 기록한 TW 시장보다 저조한 성과를 냈습니다.주가 변동성Is 7731's price volatile compared to industry and market?7731 volatility7731 Average Weekly Movement11.3%Consumer Retailing Industry Average Movement3.1%Market Average Movement6.3%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.6%안정적인 주가: 7731의 주가는 지난 3개월 동안 TW 시장보다 변동성이 컸습니다.시간에 따른 변동성: 7731의 주간 변동성(11%)은 지난 1년 동안 안정적이었지만 TW 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2015n/aYanchao Yangmarxbiotech.comMARX 바이오테크는 남성 건강 및 코스메슈티컬 제품의 온라인 소매업에 종사하고 있습니다. 이 회사는 2016년에 설립되었으며 대만 신베이시에 본사를 두고 있습니다.더 보기MARX Biotech Co., Ltd. 기초 지표 요약MARX Biotech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?7731 기초 통계시가총액NT$2.98b순이익 (TTM)NT$42.92m매출 (TTM)NT$635.85m68.1x주가수익비율(P/E)4.6x주가매출비율(P/S)7731는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표7731 손익계산서 (TTM)매출NT$635.85m매출원가NT$241.26m총이익NT$394.59m기타 비용NT$351.67m순이익NT$42.92m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)0.082총이익률62.06%순이익률6.75%부채/자본 비율85.3%7731의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당1.0%현재 배당 수익률70%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 11:21종가2026/06/10 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MARX Biotech Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).
New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).
Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).
공시 • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).
New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).
Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).
공시 • Mar 28MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025, at 09:30 Taipei Standard Time. Location: 13 floor no,659, pan nan rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).
New Risk • Jan 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.28b market cap, or US$99.6m).
공시 • Mar 16MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024.
